ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / TELO / dividends
TENX (27) SDEV (33) MAIA (32) QUCY (28) ⌘ Pro Terminal β†’

Telomir Pharmaceuticals Inc. (TELO) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.92 -2.15% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.91

Telomir Pharmaceuticals Inc. (TELO) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $67.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TELO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is TELO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Telomir Pharmaceuticals Inc. (NASDAQ: TELO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.92 (-2.15% 1D, market cap $67.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TELO ranks #863 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does TELO compare to TENX and SDEV in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TELO carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and SDEV (Stablecoin Development Corporation) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $67.3M). Among the 5-stock peer group, TELO leads on earnings multiple (N/A) while TELO leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TELO?
β–Ό

Per TELO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971532), Telomir Pharmaceuticals Inc. generated $3.1M in revenue (+454.5% YoY), -$10.4M in net income, and -$3.7M in free cash flow against $7.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.91 (-0.58%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (28/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510028
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (6)Whales (3)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$2 Bull$1 Base$1 Bear
πŸ“¬ FREE TELO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for TELO)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
πŸ” WHY TELO SCORES 28/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
36
Grade E$1.09-7.3% Next Q
Q2 (-2Q)
33
Grade E$1.01+1% Next Q
Q3 (-1Q)
31
Grade E$1.02-9.8% Next Q
Current
28
Grade E$0.92-10% Hist 90D Ξ±
Trajectory: E (36) β†’ E (28)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a TELO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While TELO currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.12) and Max Pain ($0.97) forces dealer call-delta covering toward $1.66.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TELOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œTELO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TELO)

  • βœ“Walkthrough of TELO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
TELO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.83%πŸ“ HORIZONTAL RANGE
2026-11-04O $0.94H $0.94L $0.92C $0.92VOL 58.1K
RES: $1.72SUP: $0.78SMA50: $1.12SMA200: $1.22
$1.64$1.41$1.18$0.95$0.72RES $1.72SUP $0.78$0.922026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TELO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ TELO Butterfly Map β†’ + Track TELO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +454.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TELO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for TELO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TELO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TELO)

Health Care Rank #863 of 1015 βš”οΈ TENX vs TELO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (TELO vs. TENX, SDEV, MAIA, QUCY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Telomir Pharmaceuticals Inc. (TELO) ranks #863 by composite RQD confidence (28/100, grade E) and #701 by equity capitalization ($67.4M). Within this direct 5-issuer industry benchmark cohort, TELO leads on earnings valuation at N/A trailing P/E, while TELO leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. SDEV currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with TELO at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TELO ACTIVE
Telomir Pharmaceuticals Inc.
E 28/100 β€” β€” -35.0% -2.15% $67.4M Benchmark Subject
TENX
Tenax Therapeutics Inc.
E 27/100 β€” β€” -35.0% +0.56% $67.4M /tenx-vs-telo β†’
SDEV
Stablecoin Development Corporation
E 33/100 β€” β€” -35.0% -8.91% $67.3M /sdev-vs-telo β†’
MAIA
MAIA Biotechnology Inc.
E 32/100 β€” β€” -35.0% 0.00% $67.9M /maia-vs-telo β†’
QUCY
Quantum Cyber N.V.
E 28/100 β€” 72.6% -35.0% -9.61% $66.2M /qucy-vs-telo β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001971532 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Telomir Pharmaceuticals Inc. (TELO) reported GAAP revenue of $3.1M (+454.5% vs. FY2024 revenue of $556.1K , and -94.8% cumulative change since FY2023) , GAAP net income of -$10.4M, operating cash flow of -$3.7M, and free cash flow of -$3.7M (+27.3% YoY). On the balance sheet, TELO closed FY2025 with $7.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.1M -$10.4M -$3.7M -$3.7M $7.3M β€”
FY2024 (FY) 2024-12-31 $556.1K -$16.5M -$5.1M -$5.1M $1.3M β€”
FY2023 (FY) 2023-12-31 $58.8M -$13.1M -$3.9M -$3.9M β€” β€”

3. TELO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TELO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Telomir Pharmaceuticals Inc. (NASDAQ: TELO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.92 (-2.15% 1D, market cap $67.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TELO ranks #863 in composite RQD confidence.

How does TELO compare to TENX and SDEV in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TELO carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and SDEV (Stablecoin Development Corporation) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $67.3M). Among the 5-stock peer group, TELO leads on earnings multiple (N/A) while TELO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TELO?

Per TELO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971532), Telomir Pharmaceuticals Inc. generated $3.1M in revenue (+454.5% YoY), -$10.4M in net income, and -$3.7M in free cash flow against $7.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TELO trading relative to its 50-day, 200-day, and 52-week technical levels?

TELO last traded at $0.92 (-2.15% on volume of 58,140 shares), positioning the stock -17.86% below its 50-day simple moving average ($1.12) and -24.59% below its 200-day simple moving average ($1.22). Across its 52-week range of $0.79 to $1.58, TELO sits at the 16.5% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $1.04).

Direct Sub-Reports: TELO RQD Cockpit TELO 12M Forecast TELO Earnings & Move TELO Dividends & DRIP TELO Insiders & 13F TELO Whale Options TELO Profit Sankey TELO News & Why
ROARABLE RATING BRIEF β€’ RQD 28/100 (E) βœ“ SEC XBRL & RQD VERIFIED

TELO β€” Telomir Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Telomir Pharmaceuticals Inc. (TELO) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.92 (-2.15% 1D, market capitalization $67.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of -5.19%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Telomir Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company carries a market capitalization of $0.1B. β€” describes its specific products, customers, or revenue model. The reported revenue of β€” across the financial periods indicates no reported revenue in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Telomir Pharmaceuticals Inc. (TELO) reported $3.1M in annual revenue (up from $556.1K in FY2024, +454.5% YoY) and -$10.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($58.8M revenue, -$13.1M net income) through FY2025, TELO scaled operating cash flow to -$3.7M and free cash flow to -$3.7M, backed by $7.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.19% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.79 – $1.58 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should watch for second-order effects from the financing itself, including dilution through warrants and the possibility of further equity raises if trial timelines extend beyond the cash on hand.

  • Key Question #1: Can TELO sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.1M and free cash flow of -$3.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is TELO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TELO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Telomir Pharmaceuticals Inc. (TELO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to TELO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TELO Bull vs. Bear Conversation Board β€” What's Your Call at $0.92?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TELO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TELO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $1.21 (+28.7%)
πŸ“Œ Pinned Debate

A $5.6M financing with reported backing from a billionaire co-founder positions the company to advance Telomir-Zn into a Phase I/II TNB

The street is overcomplicating Telomir Pharmaceuticals Inc. (TELO). A $5.6M financing with reported backing from a billionaire co-founder positions the company to advance Telomir-Zn into a Phase I/II TNBC trial.. With an RQD score of 28/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.02.

CapAlloc_Nerd πŸ‚ BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER β€’ Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.73 (-22.3%)
Spot @ $0.94

A -35% ROIC, three consecutive years of net losses, and an insider conviction pillar scored 3/20 leave the stock with weak fundamental

Sitting on the sidelines or leaning short TELO above $0.94. A -35% ROIC, three consecutive years of net losses, and an insider conviction pillar scored 3/20 leave the stock with weak fundamental and insider support.. Until Fundamental Cash Engine (6/20) and FCF yield (-5.19%) inflect higher, upside is capped near $1.58.

LIVE TAPE